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Abstract: Scleromyxedema	is	a	rare	chronic	cutaneous	mucinosis	of	unknown	etiology.	It	 is	characterized	by	papular	erup-
tion	and	scleroderma	with	microscopic	evidence	of	mucin	deposition,	fibroblast	proliferation,	and	fibrosis.	Most	patients	with	
scleromyxedema	have	monoclonal	gammopathy	and	systemic	manifestations	resulting	in	significant	morbidity	and	mortality.	
Several	types	of	treatment	have	been	reported	with	partial	or	inconsistent	responses.	Despite	showing	unpredictable	evolution,	
systemic	consequences	of	scleromyxedema	and	treatment	side	effects	may	result	in	death.	We	describe	a	rare	case	of	a	patient	
with scleromyxedema without paraproteinemia with systemic involvement that evolved to death despite treatment with cy-
clophosphamide.
Keywords: Autopsy;	Cyclophosphamide;	Paraproteinemias;	Scleromyxedema
s
Received on 04.03.2015
Approved	by	the	Advisory	Board	and	accepted	for	publication	on	20.07.2015
*	 Work	performed	at	Faculdade	de	Medicina	de	Jundiaí	(FMJ)	–	Jundiaí	(SP),	Brazil.
 Financial Support: None.
	 Conflict	of	Interest:	None.
1	 Universidade	Estadual	de	Campinas	(UNICAMP)	–	Campinas	(SP),	Brazil.
2	 Faculdade	de	Medicina	de	Jundiaí	(FMJ)	–	Jundiaí	(SP),	Brazil.
3	 Private	clinic	–	Vitória	(ES),	Brazil.
4	 Private	clinic	–	São	Luís	(MA)	-	Brazil.
		 ©2016	by	Anais	Brasileiros	de	Dermatologia
INTRODUCTION 
Scleromyxedema is a rare chronic cutaneous mucinosis of 
unknown	etiology.	It	affects	adults	between	30-70	years	of	age,	with	
no	gender	preference.	Typical	clinical	findings	 include:	widespread	
papular eruption with sclerodermiform appearance; monoclonal 
gammopathy; absence of thyroid disease; and the histopathologic 
triad	 (dermal	mucin	 deposition,	 fibroblast	 proliferation,	 and	 fibro-
sis).	The	absence	of	monoclonal	gammopathy	does	not	exclude	the	
diagnosis	of	scleromyxedema,	which	is	considered	an	atypical	case.1-3
In	addition	to	the	skin	changes,	most	scleromyxedema	pa-
tients present with systemic manifestations that may involve cardio-
vascular,	gastrointestinal,	respiratory,	skeletal,	muscular,	renal,	and	
nervous	systems,	causing	significant	morbidity	and	mortality.	The	
lack	of	 high-quality	 studies	 on	 the	 effectiveness	 of	 treatments	 for	
scleromyxedema and the incomplete understanding of the patho-
genesis	of	the	disease	have	prevented	the	development	of	definitive	
guidance on the best treatment approach.2,3
CASE REPORT
A	previously	healthy	 57-year-old	male	patient	 noted,	 five	
years	before,	hardening	of	the	skin	on	the	neck	and	back	associated	
with local pruritus. He reports that one year after the symptoms 
appeared	 he	 developed	 dyspnea	 on	 mild	 exertion,	 dysphagia	 to	
solids,	upper	limb	weakness,	and	polyarthralgia.	Physical	examina-
tion showed diffuse erythema associated with shiny coalescing nor-
mochromic	papules	involving	the	neck,	upper	trunk,	and	proximal	
portion	of	the	upper	limbs	(Figure	1).	Some	papules	showed	linear	
arrangement	 with	 shiny	 and	 hardened	 surrounding	 skin	 (sclero-
dermiform)	 (Figure	 2).	When	 asked	 to	 raise	his	 arms,	 he	 showed	
limited range of motion and pallor areas interspersed by erythema 
(Figure	3).
A	skin	biopsy	of	a	back	sample	revealed	mucin	deposition	
in	the	dermis	between	thick	and	dissociated	collagen	fiber	bundles,	
suggesting the diagnosis of scleromyxedema. It also revealed dense 
superficial	perivascular	 inflammatory	 infiltrates	 (Figures	4	and	5).	
Congo	red	and	PAS	stains	were	negative.	Thyroid	hormones	were	
normal and protein electrophoresis with blood and urine immuno-
fixation	was	negative	for	a	monoclonal	component.	Echocardiogra-
phy showed diastolic heart failure. 
We	 chose	 to	 start	 treatment	 with	 cyclophosphamide.	 Af-
ter	six	monthly	sessions,	however,	the	patient	experienced	clinical	
worsening	and	died.	Autopsy	revealed	mucin	deposition	in	the	ad-
ventitia	of	the	blood	vessels	of	the	heart,	lungs,	kidneys,	and	adrenal	
arteries. The cause of his death is unclear. 
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DISCUSSION
Scleromyxedema	 is	 characterized	 by	 a	 symmetrical	 erup-
tion	 of	 shiny	 firm	 papules	measuring	 2-3mm	 in	 diameter,	which	
may be presented in a linear distribution. Papules may evolve to 
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hardened	plaques,	showing	marked	sclerosis	and	hardening	of	the	
skin.	It	occurs	predominantly	on	the	face,	neck,	upper	limbs,	torso,	
and hands.3,4
In	addition	to	the	cutaneous	findings,	our	patient	present-
ed	with	cardiac,	gastrointestinal,	and	musculoskeletal	systemic	in-
volvement.	Musculoskeletal	involvement	is	one	of	the	most	common	
extracutaneous manifestations; the patient reported arthralgia and 
muscle	weakness,	a	common	complaint	 in	90%	of	cases	of	 sclero-
myxedema.	Dysphagia,	which	was	also	reported	by	our	patient,	is	
the	most	 common	 gastrointestinal	manifestation	 and	 is	 linked	 to	
esophageal dysmotility arising mainly from the upper esophagus. 
Dysphagia is most commonly found in patients with associated 
myopathy,	which	was	compatible	with	the	present	case.	Cardiovas-
cular	abnormalities,	such	as	congestive	heart	failure,	may	affect	up	
to 10% of patients with scleromyxedema. Mucin deposition in the 
myocardium and coronary arteries has been previously reported.3,5
Although	association	with	paraproteinemia	occurs	in	over	
80%	of	patients,	its	correlation	to	the	severity	or	progression	of	the	
disease is not clear. Monoclonal gammopathy is usually IgG-lamb-
da.	However,	scleromyxedema	in	the	absence	of	paraproteinemia,	
as	in	the	case	described,	is	considered	an	atypical	form	of	the	dis-
ease.3,5,6
Histopathologically,	 scleromyxedema	 is	 characterized	 by	
mucinous deposits of a heterogeneous mixture of mucopolysaccha-
rides	 acids	 that	 stain	positive	with	 alcian	blue	and	 colloidal	 iron,	
and are usually located in the mid and deep layers of the dermis. 
This deposit usually spares the papillary dermis and dissociates the 
collagen	fibers.7
Currently,	 there	 is	 no	 consensus	 on	 optimal	 treatment	 of	
scleromyxedema	because	of	the	lack	of	randomized	controlled	tri-
als,	limited	number	of	case	reports,	and	incomplete	understanding	
of the pathophysiology of the disease. Several methods have been 
used	with	varying	success,	including	melphalan,	interferon	alpha,	
autologous	 stem	 cell	 transplant,	 thalidomide,	 cyclophosphamide,	
plasmapheresis,	and	intravenous	immunoglobulin.2,3
Scleromyxedema	is	described	as	an	unpredictable	disease,	
but	is	usually	progressive,	debilitating,	and	lethal	in	the	absence	of	
a successful treatment. Death may result from complications with 
extracutaneous involvement or treatment side effects.3
Although	our	patient	presented	with	a	variety	of	cutaneous	
and	 systemic	findings,	 the	 autopsy	 results	were	 not	 correlated	 to	
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the	 clinical	 picture.	We	 observed	no	 statistically	 significant	muci-
nous	deposits	 in	 the	gastrointestinal	 tract,	 despite	 the	 symptoms;	
no mucinous deposits in renal and adrenals vessels were compat-
ible	with	 the	clinical	and	 laboratory	findings.	The	 lack	of	 correla-
tion between mucinous deposits and clinical features has already 
been reported. Montgomery described a patient presented with 
dyspnea	and	“mental	depression”	who	had	traces	of	mucin	in	the	
skin,	which	was	not	 observed	 in	 any	 internal	 organs	 at	 autopsy.8 
McCuiston,	however,	described	a	patient	with	weight	loss,	mental	
deterioration	and	psychosis.	Autopsy	revealed	mucinous	substance	
in the adventitia of the heart blood vessels and in the perivascular 
connective	tissue	of	the	kidney,	adrenals,	and	pancreas.9 Despite the 
many	neurological	symptoms,	we	found	no	mucin	deposition	in	the	
brain,	only	demyelination	and	gliosis.	Therefore,	different	findings	
in patients with scleromyxedema indicate that mucin deposit can 
not be the cause of these events.7,10q
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